Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis

Zaboli, Pardis; Abdollahi, Mohammad; Mozaffari, Shilan; Nikfar, Shekoufeh

doi:10.4103/jrpp.jrpp_17_46

Cited by 4 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These Th17-derived cells, categorized as non-classic Th1 cells, are potential targets for anti-inflammatory therapeutic goals [ 30 ] . The efficacy of various biological therapies have been demonstrated in CD [ 32 - 36 ] , further supporting the role of immune dysregulation in CD development.…”

Section: Introductionmentioning

confidence: 99%

Potential Vaccines for Treating Crohn's Disease

Rostami-Nejad

Yazdi

Nikfar

et al. 2020

ibj

Self Cite

View full text Add to dashboard Cite

CD is an inflammatory disease of the GIT and can affect several parts of the digestive system. There is a relationship between impaired mucosal barrier in the GIT of IBD patients and the role of bacteria such as MAP in CD. Apart from different therapeutic approaches for treating CD, development of a vaccine is a novel modality. In the present article, most available therapeutic opportunities in the last decade, especially the possibility of vaccines against CD, are reviewed. According to the search, availability of a new generation of vaccines against CD is expected specially tolerogenic ex vivo-derived DC-based vaccines. Regarding different locations of the challenge and the variety of clinical manifests of CD and also the type of resident antigen-presenting cells and their traffic in different parts of GIT, the results of immunotherapy with DC-based vaccines may vary case by case.

show abstract

Section: Introductionmentioning

confidence: 99%

Potential Vaccines for Treating Crohn's Disease

Rostami-Nejad

Yazdi

Nikfar

et al. 2020

ibj

Self Cite

View full text Add to dashboard Cite

show abstract

Risk of incisional hernia repair in patients with inflammatory bowel disease

et al. 2023

View full text Add to dashboard Cite

Aim Patients with inflammatory bowel disease (IBD) may undergo several abdominal surgeries with a risk of incisional hernia repair (IHR). The objectives of this study were to establish the risk of IHR and to analyse predictors of IHR after a first‐time abdominal surgery for IBD. Method This Danish nationwide register‐based cohort study (1996–2018) followed IBD patients from index operation until the date of IHR. The absolute risk was calculated as the cumulative incidence proportion treating death as a competing risk. Cox proportional hazard regression was used to compare the risk of IHR among different subtypes of IBD and to explore predictors of IHR. IBD subtypes were classified as ulcerative colitis (UC), Crohn's disease (CD) or unclassified IBD (IBD‐U). Results In total, 10 130 patients with IBD (UC 3911 [39%]; CD 4210 [41%]; IBD‐U 2009 [20%]) underwent either an open or a laparoscopic index operation. The 10‐year cumulative incidence of IHR varied between 5.0% and 6.3%, with a significantly higher risk in patients with UC and IBD‐U. Patients with UC (75.9%) and IBD‐U (91.9%) had more (two or more) abdominal surgeries in the follow‐up period compared with CD (51.9%). The risk of IHR increased dramatically with the number of surgeries, although not as markedly if a laparoscopic approach was used. Male sex, age, comorbidity, fascial dehiscence, wound infection and presence of stoma were predictors of IHR for patients with IBD. Conclusion The long‐term risk of IHR was roughly 5%–6%, with a higher risk in patients with UC and IBD‐U. Open surgical approach and number of previous surgeries were, among other things, important predictors of IHR.

show abstract

Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis

et al. 2020

View full text Add to dashboard Cite

INTRODUCTION: There are only limited data regarding the role of therapeutic drug monitoring in fistulizing Crohn's disease (CD). We investigated the association between both induction and maintenance serum infliximab concentrations and favorable therapeutic outcomes in patients with fistulizing CD. METHODS: This was a post hoc analysis of the ACCENT-II trial evaluating patients with fistulizing CD receiving induction (n = 282) and maintenance infliximab therapy (n = 139). Investigated therapeutic outcomes at both week 14 and week 54 included fistula response, complete fistula response, C-reactive protein (CRP) normalization (≤5 mg/L) in patients with an elevated baseline CRP, and a more stringent outcome of composite remission, defined as combined complete fistula response and CRP normalization. Associations between serum infliximab concentrations and outcomes were assessed by multivariable logistic regression models. RESULTS: Higher week 14 infliximab concentrations were independently associated with week 14 fistula response (odds ratio [OR]: 1.16; 95% confidence interval [CI]: 1.02–1.32; P = 0.019), and composite remission (OR: 2.32; 95% CI: 1.55–3.49; P < 0.001). Higher week 14 infliximab concentrations were also independently associated with week 54 composite remission (OR: 2.05; 95% CI: 1.10–3.82; P = 0.023). Based on receiver operating characteristic curve analysis, week 14 infliximab concentrations thresholds with combined maximal sensitivity and specificity of ≥20.2 μg/mL at week 2, ≥15 μg/mL at week 6, and ≥7.2 μg/mL at week 14 were associated with week 14 composite remission. DISCUSSION: Higher post-induction infliximab concentrations are associated with early and long-term favorable therapeutic outcomes in patients with fistulizing CD.

show abstract

Tumor necrosis factor-alpha antibodies in fistulizing crohn's disease: An updated systematic review and meta-analysis

Cited by 4 publications

References 45 publications

Potential Vaccines for Treating Crohn's Disease

Potential Vaccines for Treating Crohn's Disease

Risk of incisional hernia repair in patients with inflammatory bowel disease

Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis

Contact Info

Product

Resources

About